Autologous stromal vascular fraction-loaded hyaluronic acid/gelatin-biphasic calcium phosphate scaffold for bone tissue regeneration.
Park SS., Park M., Lee BT.
Animal Study, published in Mater Sci Eng C Mater Biol Appl (2021) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Mater Sci Eng C Mater Biol Appl (2021)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 35148865
- DOI
- 10.1016/j.msec.2021.112533
- Citations
- 13
Abstract (original English)
Bone defect augmentation with synthetic materials is crucial due to the unavoidable limitations of auto- and allografting. Although there are different promising synthetic materials for filling bone defects, the functionalization of these materials with cells is still challenging due to the lack of ideal cell sources. Here, we used stromal vascular fraction (SVF) heterogeneous cells that could be obtained from autologous adipose tissue to functionalize hyaluronic acid/gelatin-biphasic calcium phosphate (HyA-Gel/BCP) scaffolds for bone regeneration. The SVF cells were isolated, and the cellular composition and osteogenic differentiation potential were analyzed. Then, they were cultured on HyA-Gel/BCP scaffolds for in vitro characterization. An In vivo evaluation of the autologous SVF-loaded HyA-Gel/BCP scaffolds was performed using a rat skull critical-size defect model. The results showed that the SVF was successfully isolated and contained different types of cells, including mesenchymal stem like-cells with osteogenic differentiation ability. Also, the SVF cells could be cultured and expanded on the HyA-Gel/BCP scaffolds without affecting their viability. In vivo implantation of autologous SVF-loaded HyA-Gel/BCP scaffolds showed excellent bone regeneration compared to unloaded HyA-Gel/BCP scaffolds. Thus, autologous SVF-loaded HyA-Gel/BCP scaffolds could be a promising transpl
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.